N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists
摘要:
A series of dual OX(1)R/OX(2)R orexin antagonists was prepared based on a N-glycine-sulfonamide core. SAR studies of a screening hit led to compounds with low nanomolar affinity for both receptors and good oral bioavailability. One of these compounds, 47, has demonstrated in vivo activity in rats following oral administration. (C) 2008 Elsevier Ltd. All rights reserved.
Materials for high density optical recording media
申请人:Gigastorage Corporation
公开号:US20040225115A1
公开(公告)日:2004-11-11
Materials for optical recording media are disclosed. Specifically, the materials are metal chelate compounds of azo dyes, which are formed from sulfamoylated m-diaminobenzene compounds and benzene ring-containing azo compounds. Further, the invention provides an optical recording medium, characterized in that said metal chelate compounds of azo dyes are employed onto the optical recording medium to form a recording layer. The invention also discloses a process for the production of an optical recording medium.
Materials for optical recording media are disclosed. Specifically, the materials are metal chelate compounds of azo dyes, which are formed from sulfamoylated m-diaminobenzene compounds and benzene ring-containing azo compounds. Further, the invention provides an optical recording medium, characterized in that said metal chelate compounds of azo dyes are employed onto the optical recording medium to form a recording layer. The invention also discloses a process for the production of an optical recording medium.
N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists
作者:Hamed Aissaoui、Ralf Koberstein、Cornelia Zumbrunn、John Gatfield、Catherine Brisbare-Roch、Francois Jenck、Alexander Treiber、Christoph Boss
DOI:10.1016/j.bmcl.2008.09.079
日期:2008.11
A series of dual OX(1)R/OX(2)R orexin antagonists was prepared based on a N-glycine-sulfonamide core. SAR studies of a screening hit led to compounds with low nanomolar affinity for both receptors and good oral bioavailability. One of these compounds, 47, has demonstrated in vivo activity in rats following oral administration. (C) 2008 Elsevier Ltd. All rights reserved.